CTRI/2024/01/061844招募中3 期
A Prospective, Randomized, Open-labelled, Multi-centric, Parallel-group, Phase III Study to Assess the Efficacy and Safety of Febuxostat ER Tablet 40/80 mg versus Febuxostat IR Tablet 40/80 mg for treatment of chronic hyperuricemia in conditions where urate depression has already occurred (including a history, or presence of tophus and /or gouty arthritis) - NI
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female subjects of age between 18 to 65 years (both inclusive.)
- •2. Subjects with history of chronic hyperuricemia (uric acid level >6.8 mg/dL).
- •3. Subjects with history of Gout as defined by ACR criteria.
- •4. Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
排除标准
- •1. Subjects with suspected hypersensitivity to the study medication or any of the ingredients of the formulation.
- •2. Subjects with serum uric acid levels >15 mg/dl.
- •3. Subjects with abnormal Liver Function Test (LFT) with values more than 3 times the upper limit of normal.
- •4. Subjects with abnormal eGFR ( <30 mL/min/1.73 m2) will be excluded from the study.
- •5. Subjects with known case of Type 1 Diabetes will be excluded from the study.
- •6. Subjects with Type 2 Diabetes Mellitus whose diabetes has not been stable and uncontrolled for the previous three months and with HbA1c value greater than 8% will be excluded from the study.
- •7. Subjects with history of uncontrolled hypertension (systolic blood pressure =180 mmHg or diastolic blood pressure =100 mmHg) within the past 6 months.
- •8. Subjects with known case of infection with hepatitis B, hepatitis C or HIV.
- •9. Subjects with known case of symptomatic congestive heart failure, severe aortic stenosis, unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery, sinus node dysfunction and any clinically significant cardiac arrhythmias will be excluded from the study.
- •10. Subjects with known case of Stroke will be excluded from the study.
- •11. Subjects with history of any Oncological Conditions since last 5 years will be excluded from the study.
- •12. Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study.
- •13. Subjects with concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.
- •14. Subjects currently taking any of the prohibited medications(s) and inability/unwillingness to discontinue them for the entire study period.
- •15. Suspected inability or unwillingness to comply with the study procedures
研究者
相似试验
已完成
2 期
A clinical study to evaluate efficacy and safety of Seven Different Topical Formulations in Subjects Suffering from Osteoarthritis of Knee(s)CTRI/2012/05/002672Emami Limited210
已完成
不适用
A safety study of Neucrylate AN™ Liquid Embolic System for the treatment of cerebral berry aneurysmsISRCTN36582296Valor Medical Inc. (USA)40
进行中（未招募）
不适用
study to demonstrate the safety of Medical DeviceCTRI/2019/09/021038PregnanTech Ltd
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.Plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-003701-42-LTovartis Pharma Services AG1,615
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.MedDRA version: 18.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris System Organ Class: 100000004858Plaque psoriasisEUCTR2015-003701-42-PTovartis Pharma Services AG1,660